
This study leverages machine learning to identify patient subgroups with type 2 diabetes who benefit cognitively from intensive blood pressure (BP) treatment (<120 mmHg) compared to standard treatment (<140 mmHg). Using data from the ACCORD-MIND study, urinary albumin-to-creatinine ratio (UACR), Framingham risk score (FRS), triglycerides (TG), and diabetes duration emerged as key variables. Two subgroups—patients with UACR ≥65 mg/g and those with low UACR but high FRS, low TG, and long diabetes duration—demonstrated significant cognitive benefits, while no benefits were observed for others.
Like
Save
Share